Alexion Pharma (ALXN) Tops Q4 EPS by 11c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Reports Fourth Quarter and Full Year 2019 Results
January 30, 2020 6:30 AM EST4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18 4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71 Received Japanese approval for SOLIRIS® (eculizumab) for neuromyelitis optica spectrum disorder (NMOSD) Established ULTOMIRIS® (ravulizumab) as market leader for PNH in U.S., Germany and Japan within first year of launch Continued strong SOLIRIS gMG and NMOSD launches, making neurology largest franchise in U.S. Expanded pipeline with 19 clinical-stage development programs planned for 2020 across 10 assets, including 2 Factor D inhibitors, following completion of Achillion acquisition
BOSTON--(BUSINESS... More
